Economy · World
Glenmark Pharmaceuticals launches schizophrenia drug, plans innovation pivot
Glenmark Pharmaceuticals has launched a generic drug for schizophrenia and bipolar disorder in the United States. The company's chairman outlined a 10-year strategy focused on global drug innovation, involving licensing deals, partnerships, and commercialization in emerging markets.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): Business Standard, Mint